gene in chromosome 9q22, in the PTCH2 gene in 1p34, or the SUFU gene in 10q24.32. Here, we report on an 18-month-old boy presenting with medulloblastoma, frontal bossing, and multiple skeletal anomalies and his father who has basal cell carcinomas, palmar pits, macrocephaly, bifid ribs, calcification of falx cerebri, and a history of surgery for odontogenic keratocyst. These clinical findings were compatible with the diagnosis of NBCCS, and a novel mutation, c.1249delC; p.Gln417Lysfs * 15, was found in PTCH1 causing a premature stop codon. 
Nevoid basal cell carcinoma syndrome (NBCCS; OMIM 109400) is an uncommon autosomal dominant condition with multisystem involvement caused by mutations in the PTCH1 , PTCH2 , or SUFU genes. The characteristic features of the disorder are skin manifestations, jaw keratocysts, lamellar (sheet-like) calcification of the falx, childhood medulloblastoma, macrocephaly, ovarian/cardiac fibromas, and skeletal anomalies such as vertebral/rib anomalies and preaxial or postaxial polydactyly [Evans and Farndon, 2015] . Ocular anomalies seen in some cases include strabismus, congenital cataract, eyelid cysts, myelinated nerve fibers, and pigmentary changes of the retinal epithel [Chen et al., 2015] .
Skin manifestations of NBCCS include multiple and early-onset basal cell carcinomas (BCC), milia, epidermoid cysts, chalazia, comedones, and palmar and plantar pits [Gorlin, 1987] . Basal cell carcinomas can be observed early in childhood but are mostly present in early adulthood. There is an increased risk of BCC in the whole body including vulva and perianal region [Giuliani et al., 2006; Wang and Goldberg, 2007] . Hence, both increased frequency of BCCs on sun-exposed areas, such as the scalp, face, neck, chest and back, and less BCC occurrence in darker skin phenotypes support that ultraviolet exposure contributes to the cancer risk in this syndrome [Kulkarni et al., 2003 ]. These BCCs are histologically similar to the ones observed in non-NBCCS patients. Clinical diagnosis of NBCCS is based on the presence of 2 major criteria or 1 major and 2 minor criteria [Jones et al., 2011] .
PTCH1 , mapped to 9q22, is one of the genes known to cause this phenotype. PTCH1 is a tumor suppressor gene consisting of 23 exons. It encodes the protein patched homolog 1 which plays a significant role in the hedgehog signaling pathway that is extremely important for embryonic development [Gorlin, 2004] . On the other hand, PTCH2 is located at 1p34 and is highly homologous to PTCH1 . This gene encodes the protein patched homolog 2 which functions as a tumor suppressor in the hedgehog signaling pathway [Cohen, 2010] . In addition, SUFU gene mutations are also responsible for this syndrome. SUFU was mapped to 10q24.32 and encodes the suppressor of a fused homolog protein that is a negative regulator of the hedgehog signaling pathway [Evans and Farndon, 2015] . While most of the NBCCS patients bear pathogenic variants in the PTCH1 gene, SUFU mutations are less common. PTCH2 pathogenic variants were found mostly in sporadic BCC and medulloblastoma patients with somatic origin except in a Chinese Han family with NBCCS which has a germline mutation [Fan et al., 2008] . The genotype-phenotype correlation is difficult to establish for NBCCS. Patients with SUFU mutation were significantly more likely to develop a medulloblastoma than those with PTCH1 mutations; however, they were less likely to develop odontogenic keratocysts [Evans et al., 2017] .
Here, we present an 18-month-old boy with medulloblastoma and multiple congenital anomalies together with his father who has BCCs, skeletal anomalies and was operated for odontogenic keratocysts. He carries a novel frameshift mutation in the PTCH1 gene.
Clinical Reports
The patient was born at term by cesarean section with a birth weight of 4,080 g. He is the second child of nonconsanguineous parents, and he has a 7-year-old brother who has learning difficulties. He was referred to our Medical Genetics department because of his history of surgery for a histopathologically classic medullablastoma, various skeletal anomalies, and multiple congenital malformations. Clinical examination showed macrocephaly (OFC >97 percentile), frontal bossing, a coarse face, broad nasal bridge, short neck, postaxial polydactyly of the left hand and right foot as well as left cryptorchidism. He had visual and hearing loss; impaired swallowing due to the medulloblastoma operation was also observed. He was 78 cm tall (10-25th percentile), weighed 10 kg (25-50th percentile), and his OFC was 52 cm (97th percentile). His abdominal ultrasonography proved to be normal. However, X-ray examinations revealed fused ribs and vertebrae ( Fig. 1 ) . Esophagogram showed gastroesophageal reflux. His karyotype was normal, 46,XY. His father had macrocephaly, pectus carinatum, pes cavus and a history of surgeries for recurrent odontogenic keratocysts. Dermatological examination showed 3 histopathologically confirmed BCCs on the head, neck and chest ( Fig. 2 ) . Two of them, on the neck and chest region, are nodular BCCs, whereas the other is a multifocal and superficial BCC. Total excision with safe surgical margins was chosen for treatment. He also had bilateral palmar pits. Radiological examinations showed bifid rib anomalies and calcification of falx cerebri. These findings suggested NBCCS ( Table 1 ) . To prove the diagnosis, we performed molecular genetic testing for NBCCS.
Methods and Results
Genomic DNA was isolated from peripheral blood samples of the proband, his brother, and their father using MagnaPure LC DNA Isolation Kit-Large Volume and MagnaPure LC instrument (Roche Applied Science, Mannheim, Germany). Each of the 12 SUFU -coding exons and each of the 23 PTCH1 -coding exons, including flanking intronic regions, were amplified by PCR using GoTaq G2 2x MasterMix or GoTaq G2 HotStart 2x MasterMix (Promega, Southampton, UK). Products were purified using AxyPrep Mag PCR clean up beads (Appleton Woods, Birmingham, UK). DNA sequencing was performed using BigDye ® Terminator v3.1 Cycle Sequencing Kit (ABI, Life Technologies, Waltham, MA, USA). Sequencing PCR products were purified using AxyPrep Mag Dye Clean beads (Appleton Woods) and sequence analysis was performed using the ABI 3730xl DNA Analyzer (Life Technologies, Paisley, UK). We found a novel heterozygous c.1249delC; p.Gln417Lysfs * 15 mutation in the PTCH1 gene in the patient and his father, whereas the gene in his brother was found wild type ( Fig. 3 ) . This variant was not listed in the 1000 Genomes (http://browser.1000genomes. org/index.html) or in the ExAC database (http://exac.broadinstitute.org/). However, a nonsense mutation (c.1249C>T) at the same base is listed in the Catalogue of Somatic Mutations in Cancer database (COSMIC) in a skin tumor. The impact of the frameshift mutation on the protein patched homolog 1 structure and function predicted by in silico analysis was described as damaging. This frameshift mutation causes premature stop codon that may cause a nonsense-mediated decay.
Discussion
In this study, we describe a familial NBCCS case with medulloblastoma emerging from a novel frameshift mutation in the PTCH1 gene. About 5% of the patients with NBCCS develop medulloblastoma that typically occurs during the first 2 years of life, unlike the sporadic forms in which the peak incidence is at 7 years of age [Cowan et al., 1997; Amlashi et al., 2003] . The risk for medulloblastoma is up to 33% in SUFU -related NBSSC cases, whereas in PTCH1 -related NBCCS patients, the risk for medulloblastoma is lower than 2% [Smith et al., 2014] . In NBCCS, medulloblastoma tends to be of desmoplastic histology, but interestingly, our patient had a classic medullablastoma. PTCH1 is a member of Patched family encoding protein patched homolog 1 that acts as a receptor for hedgehog signaling pathway. The hedgehog signaling pathway is involved in many physiological processes, especially morphogenesis, during the embryonic development [Cohen, 2010] . In the absence of its ligand, sonic hedgehog, PTCH1 suppresses the release of another protein called Smoothened. When sonic hedgehog binds PTCH1, Smoothened releases and initiates a target gene transcription through transcription factors [Nachtergaele et al., 2013] .
PTCH1 is also a tumor suppressor gene. According to Knudson's 2-hit hypotheses, the first mutation is inherited (germline). The second hit -due to any random somatic events -can lead to cancer [Knudson, 1971] . In NBCCS, the first (germline) mutation is responsible for the dysmorphic features and the skeletal anomalies. The second hit accounts for a loss of heterozygosity and causes tumors such as BCC, medulloblastoma, and odontogenic keratocyst. PTCH1 gene mutations have also been identified in some sporadic cancers such as isolated BCCs, medulloblastoma, meningioma, breast cancer, etc. [Cohen, 2003] .
Nonsense, missense, frameshift, and splice site mutations as well as large-scale deletions or rearrangements of the PTCH1 gene were identified in NBCCS [Evans and Farndon, 2015] . However, just as the novel variant that we identified in our cases, most of the NBCCS causing mutations are frameshift type leading to premature termination codons.
NBCCS shows intra-and interfamilial variation in expression; hence, diagnosis can be challenging. In particular, medulloblastoma cases under 2 years of age may be remarkable for the diagnosis of NBCCS. Herein, we identified a novel frameshift mutation in exon 9 of the PTCH1 gene in a NBCCS case with medulloblastoma and the affected father. This frameshift mutation causes premature stop codon and is responsible for the clinical features. The proband is deceased at the age of 2 years after medulloblastoma surgery. Hence, some of his clinical features had not appeared at that time. BCC, basal cell carcinoma; NBCCS, nevoid basal cell carcinoma syndrome.
